An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination with Gemcitabine and in Combination with Chemoradiation (Capecitabine and Radiation) in Patients with Completely-Resected Pancreatic Carcinoma
Eligibility Criteria Expand/Collapse
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information.
Publication Information Expand/Collapse
An intergroup randomized phase II study of bevacizumab or cetuximab in combination with gemcitabine and in combination with chemoradiation (capecitabine and radiation) in patients with resected pancreatic carcinoma: a trial of the ECOG-ACRIN Cancer Research Group (E2204)
PMid: PMID29040974 | PMC number: PMC5828967
ECOG 2204: An intergroup phase II study of cetuxamab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely resected pancreatic adenocarcinoma (PC)